Skip to main content

Table 1 Comparison of demographic, medical and laboratory characteristics of cases and controls. Laboratory values are from the date closest to diagnosis of vaginitis (cases), or the matched rituximab dose timing (for controls)

From: Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders

  Cases (N = 16) Controls (N = 41) P value
Age 44 ± 14 46 ± 17 0.69
Diagnosis    0.53
ANCA vasculitis 11 (69%) 33 (80%)
Lupus nephritis 1 (6%) 3 (7%)
Other 4 (25%) 5 (13%)
Rituximab doses 13 ± 7 12 ± 7 0.7
Longest duration of B cell depletion 30 (27, 69) 30 (18, 53) 0.5
Cumulative duration B cell depletion (months with < 5 cells/uL) 47 (29, 84) 38 (19, 68) 0.2
CD3 (cells/uL) 1363 ± 799 1102 ± 550 0.17
CD4 (cells/uL) 863 ± 471 768 ± 333 0.43
CD8 (cells/uL) 428 ± 329 311 ± 204 0.14
WBC (thousand cells/uL) 8.0 ± 2.6 8.1 ± 3.4 0.96
IgG (mg/dL) 777 (593, 948) 692 (600, 843) 0.65
IgM (mg/dL) 26 (21, 63) 43 (22, 79) 0.46
IgA (mg/dL) 129 (61, 156) 128 (88, 173) 0.55
Ever IgG < 600 mg/dL 7 (44%) 19 (48%) 0.74
Ever IgM < 20 mg/dL 4 (25%) 9 (23%) 0.88
Ever IgA < 80 mg/dL 4 (25%) 7 (18%) 0.55
Cyclophosphamide 14 (88%) 27 (66%) 0.10
Cumulative cyclophosphamide dose [15] 750 (400, 1025) 375 (0, 750) 0.06
Late-onset neutropenia 4 (25%) 5 (12%) 0.23
Urinary tract infection 8/16 (50%) 7/41 (17%) 0.01
Co-morbidities    
Hypertension 6 (38%) 21 (51%) 0.35
COPD 1 (6%) 1 (2%) 0.48
Asthma 0 (0%) 3 (7%) 0.27
DVT 1 (6%) 3 (7%) 0.89
Colitis/UC/Crohn’s 2 (13%) 1 (2%) 0.13
Diabetes 0 (0%) 3 (7%) 0.27
  1. Values are expressed as N(%), mean ± SD, or median (interquartile range)
  2. COPD chronic obstructive pulmonary disease, DVT deep vein thrombosis, UC ulcerative colitis